{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:05:54Z","timestamp":1788797154963,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:00:00Z","timestamp":1722556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:00:00Z","timestamp":1722556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270218"],"award-info":[{"award-number":["82270218"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U22A20291"],"award-info":[{"award-number":["U22A20291"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1038\/s41375-024-02366-9","type":"journal-article","created":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T18:02:27Z","timestamp":1722621747000},"page":"2235-2245","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinical implications of residual normal plasma cells within bone marrow across various disease stages in multiple myeloma"],"prefix":"10.1038","volume":"38","author":[{"given":"Wenqiang","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihui","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3698-2072","authenticated-orcid":false,"given":"Jingyu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingna","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3885-6782","authenticated-orcid":false,"given":"Jian","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuntong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieqiong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4523-6602","authenticated-orcid":false,"given":"Chenxing","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tengteng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuaishuai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Sui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhui","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6167-3319","authenticated-orcid":false,"given":"Yan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dehui","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8752-0644","authenticated-orcid":false,"given":"Lugui","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8621-4840","authenticated-orcid":false,"given":"Mu","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4922-4614","authenticated-orcid":false,"given":"Gang","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,2]]},"reference":[{"key":"2366_CR1","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"NWCJ van de Donk","year":"2021","unstructured":"van de Donk NWCJ, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397:410\u201327.","journal-title":"Lancet"},{"key":"2366_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102284","volume":"100","author":"P Rodriguez-Otero","year":"2021","unstructured":"Rodriguez-Otero P, Paiva B, San-Miguel JF. Roadmap to cure multiple myeloma. Cancer Treat Rev. 2021;100:102284.","journal-title":"Cancer Treat Rev"},{"key":"2366_CR3","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, et al. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327:464\u201377.","journal-title":"JAMA"},{"key":"2366_CR4","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","volume":"110","author":"E P\u00e9rez-Persona","year":"2007","unstructured":"P\u00e9rez-Persona E, Vidriales MB, Mateo G, Garc\u00eda-Sanz R, Mateos MV, de Coca AG, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood. 2007;110:2586\u201392.","journal-title":"Blood"},{"key":"2366_CR5","doi-asserted-by":"publisher","first-page":"4369","DOI":"10.1182\/blood-2009-05-221689","volume":"114","author":"B Paiva","year":"2009","unstructured":"Paiva B, Vidriales MB, Mateo G, P\u00e9rez JJ, Montalb\u00e1n MA, Sureda A, et al. The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients. Blood. 2009;114:4369\u201372.","journal-title":"Blood"},{"key":"2366_CR6","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1182\/blood-2006-07-037077","volume":"109","author":"F Zhan","year":"2007","unstructured":"Zhan F, Barlogie B, Arzoumanian V, Huang Y, Williams DR, Hollmig K, et al. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood. 2007;109:1692\u2013700.","journal-title":"Blood"},{"key":"2366_CR7","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1038\/leu.2013.166","volume":"27","author":"B Paiva","year":"2013","unstructured":"Paiva B, V\u00eddriales MB, Rosi\u00f1ol L, Mart\u00ednez-L\u00f3pez J, Mateos MV, Ocio EM, et al. A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control. Leukemia. 2013;27:2056\u201361.","journal-title":"Leukemia"},{"key":"2366_CR8","doi-asserted-by":"crossref","unstructured":"Burgos L, Tamariz-Amador LE, Puig N, Cedena MT, Guerrero C, Jel\u00ednek T, et al. Definition and clinical significance of the monoclonal gammopathy of undetermined significance-like phenotype in patients with monoclonal gammopathies. J Clin Oncol. 2023;41:3019\u201331.","DOI":"10.1200\/JCO.22.01916"},{"key":"2366_CR9","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.leukres.2014.02.009","volume":"38","author":"G An","year":"2014","unstructured":"An G, Wang H, Qin X, Shi L, Xu Y, Deng S, et al. Polyclonal serum IgM level identifies a subgroup of multiple myeloma patients with low-risk clinicobiological features and superior survival. Leuk Res. 2014;38:666\u201372.","journal-title":"Leuk Res"},{"key":"2366_CR10","doi-asserted-by":"publisher","first-page":"E507","DOI":"10.1002\/ajh.24807","volume":"92","author":"T Ghosh","year":"2017","unstructured":"Ghosh T, Gonsalves WI, Jevremovic D, Dispenzieri A, Dingli D, Timm MM, et al. The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma. Am J Hematol. 2017;92:E507\u2013e12.","journal-title":"Am J Hematol"},{"key":"2366_CR11","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/ajh.25481","volume":"94","author":"MA Tschautscher","year":"2019","unstructured":"Tschautscher MA, Jevremovic D, Rajkumar V, Dispenzieri A, Lacy MQ, Gertz MA, et al. Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. Am J Hematol. 2019;94:751\u20136.","journal-title":"Am J Hematol"},{"key":"2366_CR12","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","volume":"3","author":"NC Munshi","year":"2017","unstructured":"Munshi NC, Avet-Loiseau H, Rawstron AC, Owen RG, Child JA, Thakurta A, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol. 2017;3:28\u201335.","journal-title":"JAMA Oncol"},{"key":"2366_CR13","doi-asserted-by":"publisher","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","volume":"4","author":"NC Munshi","year":"2020","unstructured":"Munshi NC, Avet-Loiseau H, Anderson KC, Neri P, Paiva B, Samur M, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;4:5988\u201399.","journal-title":"Blood Adv"},{"key":"2366_CR14","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1200\/JCO.2016.69.2517","volume":"35","author":"JJ Lahuerta","year":"2017","unstructured":"Lahuerta JJ, Paiva B, Vidriales MB, Cord\u00f3n L, Cedena MT, Puig N. et al. Depth of response in multiple myeloma: a pooled analysis of three PETHEMA\/GEM clinical trials. J Clin Oncol. 2017;35:2900\u201310.","journal-title":"J Clin Oncol"},{"key":"2366_CR15","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1182\/blood.2022016170","volume":"140","author":"B Paiva","year":"2022","unstructured":"Paiva B, San-Miguel J, Avet-Loiseau H. MRD in multiple myeloma: does CR really matter? Blood. 2022;140:2423\u20138.","journal-title":"Blood"},{"key":"2366_CR16","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/leu.2012.160","volume":"27","author":"SZ Usmani","year":"2013","unstructured":"Usmani SZ, Crowley J, Hoering A, Mitchell A, Waheed S, Nair B, et al. Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured? Leukemia. 2013;27:226\u201332.","journal-title":"Leukemia"},{"key":"2366_CR17","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1182\/blood-2011-01-332320","volume":"118","author":"J Martinez-Lopez","year":"2011","unstructured":"Martinez-Lopez J, Blade J, Mateos MV, Grande C, Alegre A, Garc\u00eda-Lara\u00f1a J, et al. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood. 2011;118:529\u201334.","journal-title":"Blood"},{"key":"2366_CR18","doi-asserted-by":"crossref","unstructured":"Engelhardt M, Kort\u00fcm KM, Goldschmidt H, Merz M. Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible. Haematologica. Published online February 15, 2024.","DOI":"10.3324\/haematol.2023.283058"},{"key":"2366_CR19","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1182\/blood-2023-180351","volume":"142","author":"W Yan","year":"2023","unstructured":"Yan W, Qiu C, Du C, Deng S, Sui W, Xu Y, et al. The specific transcriptional signature and clonal selection of MGUS-like profile predict an exceptionally favorable prognosis in patients with newly-diagnosed multiple myeloma. Blood. 2023;142:879.","journal-title":"Blood"},{"key":"2366_CR20","doi-asserted-by":"crossref","unstructured":"Paiva B, Manrique I, Dimopoulos MA, Gay F, Min CK, Zweegman S, et al. MRD dynamics during maintenance for improved prognostication of 1280 myeloma patients in TOURMALINE-MM3 and -MM4 trials. Blood. 2023;141:579\u201391.","DOI":"10.1182\/blood.2022016782"},{"key":"2366_CR21","doi-asserted-by":"publisher","first-page":"e422","DOI":"10.1016\/S2352-3026(21)00130-7","volume":"8","author":"B Diamond","year":"2021","unstructured":"Diamond B, Korde N, Lesokhin AM, Smith EL, Shah U, Mailankody S, et al. Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. Lancet Haematol. 2021;8:e422\u2013e32.","journal-title":"Lancet Haematol"},{"key":"2366_CR22","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538\u201348.","journal-title":"Lancet Oncol"},{"key":"2366_CR23","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u2013e46.","journal-title":"Lancet Oncol"},{"key":"2366_CR24","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/s41375-019-0590-x","volume":"34","author":"G An","year":"2020","unstructured":"An G, Yan Y, Xu Y, Mao X, Liu J, Fan H, et al. Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma. Leukemia. 2020;34:578\u201388.","journal-title":"Leukemia"},{"key":"2366_CR25","doi-asserted-by":"crossref","unstructured":"Mao X, Yan W, Mery D, Liu J, Fan H, Xu J, et al. Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma. Am J Hematol. 2024;99:523\u201333.","DOI":"10.1002\/ajh.27207"},{"key":"2366_CR26","doi-asserted-by":"crossref","unstructured":"Pernice S, Sirovich R, Grassi E, Viviani M, Ferri M, Sassi F, et al. CONNECTOR, fitting and clustering of longitudinal data to reveal a new risk stratification system. Bioinformatics. 2023;39:btad201.","DOI":"10.1093\/bioinformatics\/btad201"},{"key":"2366_CR27","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.ccell.2023.05.007","volume":"41","author":"M Dang","year":"2023","unstructured":"Dang M, Wang R, Lee HC, Patel KK, Becnel MR, Han G, et al. Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease. Cancer Cell. 2023;41:1032\u201347.e4.","journal-title":"Cancer Cell"},{"key":"2366_CR28","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","volume":"1","author":"O Zavidij","year":"2020","unstructured":"Zavidij O, Haradhvala NJ, Mouhieddine TH, Sklavenitis-Pistofidis R, Cai S, Reidy M, et al. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nat Cancer. 2020;1:493\u2013506.","journal-title":"Nat Cancer"},{"key":"2366_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33944-z","volume":"13","author":"R Boiarsky","year":"2022","unstructured":"Boiarsky R, Haradhvala NJ, Alberge JB, Sklavenitis-Pistofidis R, Mouhieddine TH, Zavidij O, et al. Single cell characterization of myeloma and its precursor conditions reveals transcriptional signatures of early tumorigenesis. Nat Commun. 2022;13:7040.","journal-title":"Nat Commun"},{"key":"2366_CR30","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/leu.2010.320","volume":"25","author":"B Paiva","year":"2011","unstructured":"Paiva B, P\u00e9rez-Andr\u00e9s M, V\u00eddriales MB, Almeida J, de las Heras N, Mateos MV, et al. Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma. Leukemia. 2011;25:697\u2013706.","journal-title":"Leukemia"},{"key":"2366_CR31","doi-asserted-by":"crossref","unstructured":"Dhodapkar MV. The immune system in multiple myeloma and precursor states: lessons and implications for immunotherapy and interception. Am J Hematol. 2023;98 Suppl 2(Suppl 2):S4-S12.","DOI":"10.1002\/ajh.26752"},{"key":"2366_CR32","doi-asserted-by":"crossref","unstructured":"Poos AM, Prokoph N, Przybilla MJ, Mallm JP, Steiger S, Seufert I, et al. Resolving therapy resistance mechanisms in multiple myeloma by multi-omics subclone analysis. Blood. 2023;142:1633\u201346.","DOI":"10.1182\/blood.2023019758"},{"key":"2366_CR33","doi-asserted-by":"crossref","unstructured":"Misund K, Hofste Op Bruinink D, Coward E, Hoogenboezem RM, Rustad EH, Sanders MA, et al. Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence. Leukemia. 2022;36:1887\u201397.","DOI":"10.1038\/s41375-022-01597-y"},{"key":"2366_CR34","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3324\/haematol.2012.067272","volume":"98","author":"RJ Pessoa de Magalh\u00e3es","year":"2013","unstructured":"Pessoa de Magalh\u00e3es RJ, Vidriales MB, Paiva B, Fernandez-Gimenez C, Garc\u00eda-Sanz R, Mateos MV, et al. Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematologica. 2013;98:79\u201386.","journal-title":"Haematologica"},{"key":"2366_CR35","doi-asserted-by":"crossref","unstructured":"Szalat R, Anderson K, Munshi N. Role of minimal residual disease assessment in multiple myeloma. Haematologica. 2024.","DOI":"10.3324\/haematol.2023.284662"},{"key":"2366_CR36","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1182\/bloodadvances.2023010821","volume":"8","author":"B Paiva","year":"2023","unstructured":"Paiva B, Zherniakova A, Nu\u00f1ez-C\u00f3rdoba JM, Rodriguez-Otero P, Shi Q, Munshi NC, et al. Impact of treatment effect on MRD and PFS: an aggregate data analysis from randomized clinical trials in multiple myeloma. Blood Adv. 2023;8:219\u201323.","journal-title":"Blood Adv"},{"key":"2366_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40966-8","volume":"14","author":"DG Coffey","year":"2023","unstructured":"Coffey DG, Maura F, Gonzalez-Kozlova E, Diaz-Mejia JJ, Luo P, Zhang Y, et al. Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma. Nat Commun. 2023;14:5335.","journal-title":"Nat Commun"},{"key":"2366_CR38","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1038\/leu.2017.29","volume":"31","author":"J Flores-Montero","year":"2017","unstructured":"Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, Garc\u00eda-S\u00e1nchez O, B\u00f6ttcher S, et al. Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31:2094\u2013103.","journal-title":"Leukemia"},{"key":"2366_CR39","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1200\/JCO.21.02228","volume":"40","author":"RM de Tute","year":"2022","unstructured":"de Tute RM, Pawlyn C, Cairns DA, Davies FE, Menzies T, Rawstron A, et al. Minimal residual disease after autologous stem-cell transplant for patients with myeloma: prognostic significance and the impact of lenalidomide maintenance and molecular risk. J Clin Oncol. 2022;40:2889\u2013900.","journal-title":"J Clin Oncol"},{"key":"2366_CR40","doi-asserted-by":"crossref","unstructured":"Liu J, Yan W, Fan H, Xu J, Li L, Du C, et al. Clinical benefit of autologous stem cell transplantation for multiple myeloma patients achieving undetectable minimal residual disease after induction treatment. Cancer Res Commun. 2023;3:1770\u201380.","DOI":"10.1158\/2767-9764.CRC-23-0185"},{"key":"2366_CR41","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1182\/blood-2023-185661","volume":"142","author":"C Guerrero","year":"2023","unstructured":"Guerrero C, Termini R, Garc\u00e9s J-J, Calasanz MJ, R\u00edos R, Cabezudo E, et al. Kinetics and biology of circulating tumor cells (CTCs) and Measurable Residual Disease (MRD): two dynamic high-risk clones in multiple myeloma (MM). Blood. 2023;142:871.","journal-title":"Blood"},{"key":"2366_CR42","doi-asserted-by":"crossref","unstructured":"Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, et al. Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial. Lancet Haematol. 2023;10:e890-e901.","DOI":"10.1016\/S2352-3026(23)00236-3"},{"key":"2366_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00951-2","volume":"13","author":"J \u00d3skarsson","year":"2023","unstructured":"\u00d3skarsson J, R\u00f6gnvaldsson S, Thorsteinsdottir S, Aspelund T, Gunnarsson SB, H\u00e1konard\u00f3ttir GK, et al. Determining hemodilution in diagnostic bone marrow aspirated samples in plasma cell disorders by next-generation flow cytometry: proposal for a bone marrow quality index. Blood Cancer J. 2023;13:177.","journal-title":"Blood Cancer J"},{"key":"2366_CR44","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/bjh.15075","volume":"181","author":"Y Bai","year":"2018","unstructured":"Bai Y, Orfao A, Chim CS. Molecular detection of minimal residual disease in multiple myeloma. Br J Haematol. 2018;181:11\u201326.","journal-title":"Br J Haematol"},{"key":"2366_CR45","doi-asserted-by":"crossref","unstructured":"Lakhwani S, Rosi\u00f1ol L, Puig N, Pico-Picos MA, Medina-Gonz\u00e1lez L, Mart\u00ednez-L\u00f3pez J, et al. Recovery of uninvolved heavy\/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection. Haematologica. 2024;109:1909\u201317.","DOI":"10.3324\/haematol.2023.284154"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02366-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02366-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02366-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T11:04:20Z","timestamp":1727435060000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02366-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,2]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["2366"],"URL":"https:\/\/doi.org\/10.1038\/s41375-024-02366-9","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,2]]},"assertion":[{"value":"26 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the Blood Diseases Hospital. Written informed consent was obtained from all patients to publish this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate statement"}}]}}